GraniteShares Advisors LLC Sells 2,450 Shares of Boston Scientific Co. (NYSE:BSX)

GraniteShares Advisors LLC decreased its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 14.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,950 shares of the medical equipment provider’s stock after selling 2,450 shares during the period. GraniteShares Advisors LLC’s holdings in Boston Scientific were worth $1,246,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Lake Street Advisors Group LLC boosted its position in shares of Boston Scientific by 4.3% during the 4th quarter. Lake Street Advisors Group LLC now owns 7,629 shares of the medical equipment provider’s stock valued at $681,000 after purchasing an additional 317 shares in the last quarter. Kirtland Hills Capital Management LLC boosted its position in shares of Boston Scientific by 2.7% during the 4th quarter. Kirtland Hills Capital Management LLC now owns 10,243 shares of the medical equipment provider’s stock valued at $915,000 after purchasing an additional 266 shares in the last quarter. Cavalier Investments LLC boosted its position in shares of Boston Scientific by 148.4% during the 4th quarter. Cavalier Investments LLC now owns 178,431 shares of the medical equipment provider’s stock valued at $15,937,000 after purchasing an additional 106,590 shares in the last quarter. Illinois Municipal Retirement Fund boosted its position in shares of Boston Scientific by 13.9% during the 4th quarter. Illinois Municipal Retirement Fund now owns 184,802 shares of the medical equipment provider’s stock valued at $16,507,000 after purchasing an additional 22,504 shares in the last quarter. Finally, FourThought Financial Partners LLC bought a new stake in shares of Boston Scientific during the 4th quarter valued at about $263,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Jeffrey B. Mirviss sold 4,675 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the transaction, the executive vice president now directly owns 28,454 shares of the company’s stock, valued at approximately $2,966,329.50. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the transaction, the executive vice president now directly owns 5,502 shares of the company’s stock, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 144,305 shares of company stock valued at $14,954,985. 0.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

BSX has been the topic of several research analyst reports. Citigroup upped their target price on Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Royal Bank of Canada increased their price target on Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Canaccord Genuity Group increased their price target on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Raymond James increased their price target on Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a report on Thursday, February 6th. Finally, UBS Group increased their price target on Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Two analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $107.39.

Boston Scientific Stock Performance

Shares of BSX opened at $100.93 on Wednesday. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $148.94 billion, a price-to-earnings ratio of 80.74, a PEG ratio of 2.79 and a beta of 0.80. The stock has a 50 day moving average of $98.46 and a 200 day moving average of $89.87. Boston Scientific Co. has a 12 month low of $65.52 and a 12 month high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, sell-side analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.